Genetic alterations drive metabolic reprograming to meet increased biosynthetic precursor and energy demands for cancer cell proliferation and survival in unfavorable environments. A systematic study of gene-metabolite regulatory networks and metabolic dysregulation should reveal the molecular mechanisms underlying prostate cancer (PCa) pathogenesis. Herein, we performed gas chromatography-mass spectrometry (GC-MS)-based metabolomics and RNA-seq analyses in prostate tumors and matched adjacent normal tissues (ANTs) to elucidate the molecular alterations and potential underlying regulatory mechanisms in PCa. Significant accumulation of metabolic intermediates and enrichment of genes in the tricarboxylic acid (TCA) cycle were observed in tumor tissues, indicating TCA cycle hyperactivation in PCa tissues. In addition, the levels of fumarate and malate were highly correlated with the Gleason score, tumor stage and expression of genes encoding related enzymes and were significantly related to the expression of genes involved in branched chain amino acid degradation. Using an integrated omics approach, we further revealed the potential anaplerotic routes from pyruvate, glutamine catabolism and branched chain amino acid (BCAA) degradation contributing to replenishing metabolites for TCA cycle. Integrated omics techniques enable the performance of network-based analyses to gain a comprehensive and in-depth understanding of PCa pathophysiology and may facilitate the development of new and effective therapeutic strategies.
Introduction
Prostate cancer (PCa) is the second most common malignancy in men worldwide; in 2015, PCa accounted for 26% of male cancer cases in the United States.
1,2 Although the 5-year progression-free survival for early-stage PCa is over 90%, the prognosis for patients diagnosed at an advanced stage is poor. 3 Although current clinical pathological parameters, such as the tumor stage, Gleason score (GS) and prostate-specific antigen (PSA), are widely used, they are inadequate to predict patient outcomes. 4 Therefore, deep insight into the metabolic reprograming and genetic alterations underlying prostate tumorigenesis and cancer progression is necessary and would benefit the personalized prevention, intervention and reduction of mortality in PCa patients. Metabolic reprograming is the key signature of cancer cells and is usually driven by oncogenic signaling pathways. 5 One of the most important metabolic characteristics in PCa is an increased citrate oxidation because of the inability of the epithelial cells to accumulate zinc. The resulting low zinc concentration allows m-aconitase (ACO2) to be active, citrate to be isomerized and the previously truncated TCA cycle to be completed. [6] [7] [8] This transformation from citrate accumulation in normal epithelial cells to the citrate oxidation in prostate cancer cells may benefit to provide more efficient energy production. 6 Acetyl-coenzyme A (acetyl-CoA) is essential for citrate synthesis. Increased uptake of fatty acids 9 and overexpression of enzymes involved in b-oxidation 10 were observed in prostate tumors, which can provide ATP and acetyl-CoA to main accelerated citrate oxidation. 6, 9 In addition, due to the augmentation of membrane synthesis in malignant cells, phosphocholine, total choline containing compounds and creatine levels are elevated in PCa compared to normal tissues. 11 Notably, a strategy integrating metabolomics with transcriptomics has been employed as a novel approach to gain further insight into cancer pathophysiology and potential therapeutic targets. 12, 13 It was reported that adenosine triphosphate (ATP) citrate lyase (ACLY) depletion suppresses fatty acid (FA) elongation from C 16 to C 18 in triglycerides (TGs) and reduces the expression of carnitine palmitoyltransferase 1A (CPT1A), indicating that ACLY plays important roles in FA elongation and oxidation in LNCaP cells. 13 In addition, multi-omics data have demonstrated that the mammalian target of rapamyc in complex 1 (mTORC1) activation promotes glutamine (Gln) anaplerosis for the tricarboxylic acid (TCA) cycle by stimulating glutamate dehydrogenases (GLUDs) in cancer cells. 14 Patient tissue samples can be analyzed to characterize the in vivo variabilities in human tumors that are not available in cell lines or animal models. Multiomics analysis in PCa tissues outlined the highly deregulated metabolism in fatty acids, sphingolipids, polyamines; 15 cysteine and methionine metabolism; nicotinamide adenine dinucleotide metabolism and hexosamine biosynthesis. 16 Although many studies have indicated the accelerated TCA cycle in PCa cells, 7, 8, 17 the corresponding metabolic reprograming and potential mechanisms remain unelucidated. In our study, we used gas chromatography-mass spectrometry (GC-MS)-based metabolomics method 18 and RNA sequencing to investigate the alterations of PCa in both metabolic and transcriptional levels among the matched PCa tissues and adjacent normal tissues (ANTs). To our knowledge, there are no such studies to investigate the TCA cycle metabolism in PCa specifically through integrated omics approach and correlation analysis. By integrating metabolomics and transcriptomics, we aimed to unravel the molecular abnormalities in the TCA cycle and the potential regulatory networks underlying metabolic reprograming in PCa, which may provide new insight into the molecular mechanism study and help to draw new scientific hypothesis on prostate cancer.
Materials and Methods

Study population and sample collection
Prostate cancer tissues (PCTs) and matched ANTs from 21 patients collected from Shanghai Changhai Hospital were selected as a discovery set for metabolic profiling analysis. A second independent set of 50 tumor tissues and 50 ANTs for metabolic findings' validation were also collected, and of these, 49 paired tissues were matched. Among the 21 pairs of tumors and ANTs in discovery set, 20 pairs were selected to perform RNA sequencing. All the tumor tissues and ANTs were obtained by radical prostatectomy. Hematoxylin and eosin stained (H&E) slides were examined by pathologists to ensure the tumor tissues had high-density cancer foci, while tissue that was 5 mm physical distance to the nearest cancer What's new? Although many studies have reported accelerated tricarboxylic acid (TCA) cycle in prostate cancer (PCa) cells, the underlying metabolic reprogramming and molecular mechanisms remain elusive. Here, the authors systematically investigated the molecular changes in TCA cycle through metabolomics and transcriptomics analysis of matched normal and PCa tissues. Fumarate and malate were found to be highly correlated with tumor progression and expression of related genes. Potential anaplerotic routes from pyruvate, glutamine catabolism, and BCAA degradation contributed to replenishing metabolites for TCA cycle. These observations provide new molecular insight into PCa carcinogenesis and may facilitate the development of new and effective therapeutic strategies.
focus was selected as adjacent tissue, which was further checked by the experienced pathologist to guarantee the tissue is normal. To maximumly reduce the possible influence from stroma cells and ensure the comparability between ANTs and PCTs, the consensus criteria of 70% was adopted, that is the specialist in urological pathology checks each slice of the cancer tissue and adjacent normal tissue to make sure that epithelial cells are >70%. Detailed sample information is provided in Table 1 . The experimental protocols were approved by the institutional review boards, and informed consent was obtained from all subjects.
Metabolites extraction and derivatization
Fresh tissue samples were sheared and weighed when still frozen. 300 lL ice-cold methanol/water (4:1 v/v; 20 lg/mL tridecanoic acid as the internal standard) was added, and then vortexed for 30 sec. Subsequently, the samples were submitted to mixed grinding apparatus (MM-400 Retsch, Haan, Germany) for homogenization (25 Hz, 1 min). The mixture was centrifuged (13,000 rpm, 48C, 15 min) to precipitate proteins and tissue residues. After that, 200 lL supernatant was transferred for vacuum drying and stored at 2808C until analysis. A two-step derivatization that includes oximation and silylation reactions was performed to improve the volatility of metabolites before GC-MS analysis. Briefly, the dried tissue sample was added with 50 lL methoxyamine pyridine solution (20 mg/mL) and incubated for 2 hr in 408C water bath, followed by 1 hr silylation reaction with 40 lL MSTFA. Eventually, each derivatized sample was centrifuged at 13,000 rpm, 48C for 15 min, and the supernatant was used for GC-MS analysis. To eliminate system error during metabolites extraction process, the ANTs and PCTs were handled randomly.
GC-MS analysis
A GC-MS-based pseudotargeted metabolomic approach was employed to acquire metabolic profiling data of tissue samples. The GC-MS-based pseudotargeted method, as previously described, 18, 19 is a novel metabolomics method, it collects the metabolome data of each sample using GC-MS-SIM mode based on the characteristic ion information obtained from full scan data of GC-MS from the quality control (QC) sample which is a mixture of equal each real sample. The first step of the pseudotargeted method is to define characteristic ions for preparing the selective ion monitoring (SIM) table. The QC sample was analyzed using a GCMS-QP 2010 instrument equipped with an AOC-20i autosampler (Shimadzu, Kyoto, Japan) at full-scan mode. The injection volume was 1 lL. Derivatized metabolites were separated by a DB-5 MS capillary column (30 m 3 250 lm 3 0.25 lm, Agilent Technologies, Palo Alto, CA). The flow rate of helium (carrier gas) was set at 1.19 mL/min. The oven temperature was initially held at 708C for 3 min and then ramped to 3008C at 58C/min and maintained for 10 min. The inlet, interface and ion source temperatures were 300, 280 and 2308C, respectively. Electron impact (EI, 70 eV) was employed as the ionization mode, and the voltage of the detector was manipulated in accordance with the tuning results. Mass acquisition ranged from 33 to 600 (m/z), and the even time and solvent delay were 0.2 sec and 6.0 min, respectively.
After collecting the metabolic profile of QC sample at full scan mode, the next step is metabolite identification and feature ion selection. The full scan data were imported into AMDIS 2.62 (NIST, Gaithersburg, USA) for peak detection and deconvolution. Metabolite identification was based on commercially available libraries (NIST 11, Gaithersburg, USA). Available reference standards were used to confirm the metabolite identification results using the retention time, retention index and mass spectra. The feature ions selection of the metabolites was performed using ChromaTOF (LECO, Saint Joseph, USA) software to produce a SIM table including feature ions and their time range information. In final step, at the same operational conditions as for full scan, real samples were analyzed to collect tissue metabolic profiling data at a SIM mode. One QC sample was run after every 10 real samples to monitor the repeatability and reliability of the analytical method.
RNA sequencing
RNA library construction and sequencing, RNA data preprocessing and read mapping were performed as previously described. 20 Briefly, beads containing oligo (dT) were used to isolate mRNA from total RNA, cDNA library preparation and sequencing were conducted on an Illumina HiSeq TM 2000 sequencing machine based on standard protocols. Using a base-calling pipeline, we converted the images generated by the sequencers into nucleotide sequences, and dirty raw reads were removed. Reads that could be uniquely mapped to a gene were used to calculate the expression level. The number of uniquely mapped reads per kilobase of exon region per million mapped reads (RPKM) value was calculated as the gene expression level, because RPKM method can eliminate the influence of different gene lengths and sequencing discrepancies on the gene expression calculation. 20 
Immunohistochemistry
Immunohistochemistry was performed on paraffinembedded, 10-lm sections using antibodies against pyruvate dehydrogenase complex component X (PDHX, dilution 1:100, Abcam, Cambrige, UK), pyruvate carboxylase (PC, dilution 1:100, Abcam, Cambrige, UK), glutaminase (GLS, dilution 1:100, Abcam, Cambrige, UK), glutamate dehydrogenase 1 (GLUD1, dilution 1:100, Abcam, Cambrige, UK), glutamate dehydrogenase 2 (GLUD2, dilution 1:100, Abcam, Cambrige, UK) and branched chain amino acid transaminase 2 (BCAT2, dilution 1:100, Abcam, Cambrige, UK). The slides were deparaffinized and antigen retrieval was performed using sodium citrate retrieval solution at pH 6. The sections were stained by the immunoperoxidase technique using a 3,3 0 -diaminobenzidine (DAB) substrate (Invitrogen, Waltham, USA) and counterstained with hematoxylin.
Statistical analysis
The quantitative table of the feature ions of the metabolites was imported into GCMS solution 2.7 (Shimadzu, Kyoto, Japan) for the batch integration of all samples. A two-sided Wilcoxon signed rank test was performed in MATLAB (R2014a, MathWorks, Natick, USA) to identify differential metabolites and genes between paired tumor tissues and ANTs. The pattern of metabolic changes with disease progression (according to the GS or tumor stage) was evaluated by pattern correlation analysis using MetaboAnalyst 2.0. 21 SIMCA-P 11.0 (Umetrics, Umea, Sweden) software was used to conduct principal component analysis (PCA), partial least square-discriminate analysis (PLS-DA) and orthogonal signal correction filtered PLS-DA (OSC-PLS-DA). Metabolite clustering was implemented using hierarchical clustering in Multi Experiment Viewer (MEV) software. 22 Spearman correlation analysis was conducted using SPSS 18.0 (IBM, Armonk, NY) software. Gene set enrichment analysis (GSEA) software (Broad Institute, Cambridge, MA) was used to discover the sets of related genes that might be systematically changed in PCa tissue. The methodology of GSEA was described in more details elsewhere. 23 
Results
Metabolic signatures of PCa tissue
The results from the linearity (Supporting Information Table  S1 ) and recovery (Supporting Information Table S2 ) evaluation study suggested that the pseudotargeted method is sufficiently robust to monitor metabolites with diverse properties and a range of different concentrations. The detailed information was attached in the Supporting Information materials. In total, 383 features were detected using our pseudotargeted method, 18, 19 381 features were retained after peak integration and refining according to 80% rules. 24 The original data were calibrated by internal standard (tridecanoic acid) and the tissue weight. QC samples were used to assess the quality of the metabolomics data. On the PCA score plot (Supporting Information Fig. S1a) , the QC samples clustered tightly, indicating the satisfactory repeatability and robustness of our method. To further investigate the metabolic distinction between malignant tissues and matched ANTs, we performed PLS-DA analysis. Although clear separation of PCTs from ANTs was obtained (Supporting Information Fig. S1b) , PLS-DA model was overfitted. We further performed OSC-PLS-DA analysis, the discrimination between PCTs and ANTs was more obvious (Fig. 1a) , the permutation test showed that the model was reliable and had no overfitting (Fig. 1b) .
Then a two-sided Wilcoxon signed rank test was performed to identify differential metabolites. FDR was calculated to account for multiple testing, and the metabolite with p-values < 0.05 and FDR < 0.1 was considered statistically significant. Among the 137 identified metabolites, 55 metabolites involving in urea cycle, TCA cycle and metabolism of carbohydrates, glutathione, amino acids, FAs and glycerolipids were found to be significantly changed in tumor tissues. Their detailed information is presented in Supporting Information Table S3 . Then we conducted hierarchical clustering of the 55 metabolites and the heat map was illustrated in Figure 1c . Interestingly, some of the tumor tissues seem to have a similar metabolite profile to normal tissue, while others show different metabolite profiles. Then clustering of the samples was performed (Fig. 1d) . We found that most of the PCTs showed marked different metabolite profiles from ANTs, while four PCTs (T5, T7, T20 and T3) showed similar metabolic profiling to ANTs. Besides, there are also disparate metabolic profiles among different tumor tissues. Similar findings have been reported in previous literatures. [25] [26] [27] [28] [29] This observation may be an appearance of tumor heterogenicity because of influences by complicated factors, like GS, tumor stage and individual difference.
Validation of the metabolites changes by another independent cohort
To verify the above findings, an additional independent 50 ANTs and 50 PCTs were collected and subjected to metabolomics analysis. The same statistical analysis method as in discovery set was used. Finally, 45 of the 55 differential metabolites were validated, the fold changes and p-values were given in Supporting Information Table S3 .
Correlation of metabolite levels with tumor progression
To explore the correlation of metabolite levels with tumor progression, the samples were divided into different groups. Pearson Correlation Analysis was performed between metabolite levels and the given group pattern. A metabolite with p-values < 0.05 and FDR < 0.1 was considered statistically significant. The correlations and p-values of these metabolites with tumor stage and GS were presented in Supporting Information Tables S4 and S5. In general, fumarate and malate involved in TCA cycle, 11-eicosenoic acid, docosanoic acid, eicosanoic acid, etc. in fatty acid metabolism and dihydrocholesterol, glycerol-2-phosphate, glycerol-3-phosphate, 5-methyluridine, etc. were correlated with both tumor stage and GS (Supporting Information Table S3 ). Besides, we also investigated the correlation of metabolite levels with tumor progression in ANTs, no correlation was found.
Gene expression alteration in PCa tissue
In total, 22,684 transcripts were analyzed. The criteria to identify differentially expressed genes between ANTs and 
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PCTs were set as: p < 0.05, FDR < 0.1 and fold change >1.5. 6,165 genes were differentially expressed with 1,861 downregulated and 4,304 upregulated genes in tumor tissues, which is visualized on a heat map (Fig. 2a) . As in metabolomics data, some tumor samples showed similar variations to normal tissues. Then clustering of the tissue samples was also performed (Fig. 2b) , and three PCTs (T25, T7 and T5) were found distributed in the part of ANTs. Compared to Figure  1d , the clustering result in Figure 2b was less complex, indicating the metabolite abundance was more susceptible to other factors. Then we performed GSEA to evaluate microarray data at the level of gene sets, using all the gene expression data we obtained. The top 15 enriched gene sets are illustrated in Figure 2c . Among them, valine, leucine and isoleucine degradation and the TCA cycle were remarkably enriched (Figs. 2d and 2e) . Next, we focused on the metabolites and transcript alterations of the TCA cycle to unravel the regulation network underling PCa progression.
Metabolites and gene expression changes in TCA cycle
Significant accumulations of the TCA cycle intermediate metabolites, including malate, fumarate, succinate and 2-hydroxyglutaric acid (2-HG), were observed in PCTs in both discovery set (Fig. 3a) and validation set (Fig. 3b) . The levels of fumarate and malate were also correlated with GS and tumor stage in two separated sets (Figs. 3c-3f) . Interestingly, the expression levels of most genes involved in the TCA cycle were significantly upregulated in the prostate tumor tissues. Particularly, the expression levels of CS, ACLY, IDH1, IDH2, IDH3B, IDH3G, SUCLG2, SDHA, SDHB, FH, MDH1 and MDH2 were correlated with GS ( Fig. 3g ) and tumor stage (Fig. 3h) . We also investigated the publicly available data sets on PCa [30] [31] [32] [33] [34] and not only similarities but also differences were found across different databases (Supporting Information Table S6 ) due to the race origin, individual differences or other complicated factors. Of interest is that most of the significantly expressed genes (10/13) in data set 3 33 was similar to our results.
To investigate the association between metabolites and genes in TCA cycle, we mapped genes to metabolites through the biochemical reaction they catalyzed. The gene's enzyme product catalyzes the reaction that produces or consumes the metabolite, such metabolite-gene was termed a pair. Thirty pairs were connected to each other through a metabolic reaction in TCA cycle. Spearman correlation analysis of each metabolite-gene pair across tumor and normal tissues was performed. Intriguingly, only the differential metabolites fumarate and malate were significantly correlated with the related genes in the tumor tissues but not in the adjacent normal counterparts (Fig. 3i, Supporting Information Table  S7 ). These findings indicate that the metabolite-gene associations of fumarate and malate are enhanced in tumors.
Associations between TCA cycle and the potential anaplerotic routes Next, we mapped the metabolites and genes to the TCA cycle and associated pathways to investigate the potential mechanisms underlying the activated TCA cycle (Fig. 4a) . To do this, several key metabolites or enzymes that control the flux into and out of TCA cycle were centered on. One important enzyme was ACO2 that catalyzes the first step in the oxidation of citrate via the TCA cycle, 8 an increased ACO2 expression in PCT (Fig. 4a) was observed.
Pyruvate dehydrogenase (PDH) complex contributes to transforming pyruvate into acetyl CoA for citrate synthesis. 35 PDHA1, PDHB and PDHX were found to be upregulated in malignant tissues (Fig. 4a) . We also performed immunohistochemistry analysis of PDHX and found that PDHX was highly expressed in 21 of 25 (84.00%) PCa tissue pathological sections (Fig. 4b) .
Pyruvate can also replenish TCA cycle by generating oxaloacetate (OAA) via PC. MDH1 and MDH2 catalyze the bidirectional reaction between malate and OAA. A significant correlation between PC expression and malate levels in tumor tissues (p 5 0.0336) but not in normal tissues (p 5 0.9950) was observed, suggesting that pyruvate-derived OAA may be an important source of malate in PCa.
The expression levels of GLS, GLUD1 and GLUD2 contributed to the transformation of Gln into 2-KG and the levels of IDH1, IDH2, IDH3A, IDH3B and IDH3G were increased in tumor tissues (Fig. 4a) . Significantly increased levels of 2-HG, 2-KG, Gln and glutamate were observed in the validation cohort (Fig. 3b) . Glutaminase (GLS) is a key enzyme that converts Gln into glutamate. 36 GLS expression is positively regulated by the oncogenic transcriptional factor cMyc via its suppression by miR-23. 37 We observed that MYC (Fig. 4a ) and GLS were upregulated, whereas miR-23b-3p (Fig. 4c) and miR-23b-5p (Fig. 4d) were decreased in tumor tissues, indicating that MYC-regulated Gln anaplerosis may contribute to driving the TCA cycle in PCa.
In addition, branched chain amino acid (BCAA) degradation can produce succinyl-CoA in the cell by generating propionyl-CoA from valine and isoleucine 38 and, subsequently, providing substrates for the TCA cycle (Fig. 4a) . We analyzed the correlations among fumarate, malate and succinate and the expression of 44 BCAA degradation genes (Figs. 5a and 5b, Supporting Information Table S8 ). In the ANTs, few gene expression levels were significantly correlated with the levels of fumarate, malate and succinate. Interestingly, in the PCTs, the expression levels of most genes showed a significant correlation with the TCA metabolites.
To evaluate the expression levels of vital genes involved in pyruvate anaplerotic pathway, glutamine catabolism and BCAA degradation in ANTs and PCTs, immunohistochemical analyses of PC, GLS, GLUD1, GLUD2 and BCAT2 were performed. We found that PC, GLS, GLUD1, GLUD2 and BCAT2 were highly expressed in 7/10, 9/10, 8/10, 8/10 and 6/10 PCT pathological sections (Figs. 5c-5g) . These results were consistent with the transcriptome data.
Discussion
In our study, metabolomics and transcriptomics were integrated to investigate the metabolites and transcripts alterations in PCa. Totally, 45 metabolites were found and validated to be differentially regulated in tumor tissues and were mapped to urea cycle, TCA cycle and metabolism of carbohydrates, glutathione, amino acids, FAs and glycerolipids. The elevated levels of FAs and glycerolipids, 9,29 myoinositol, 39 alanine, 40 uracil, glycerol-3-phosphate and proline 25 have been observed in previously published literatures, which were consistent with our findings. Besides, GSEA was performed to interpret the gene expression results and generated the most enriched pathways in tumor tissues. Due to the significant enrichment of genes and accumulation of metabolites in TCA cycle, we centered on the molecular alterations and potential mechanism regulated in TCA cycle underlying PCa.
The marked accumulations of malate, fumarate, succinate and 2-HG were observed in prostate tumor tissues. The mutation of genes encoding succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) can result in the accumulation of succinate, fumarate and 2-HG, respectively, as found in paraganglioma, leiomyoma, papillary renal carcinoma and glioma, [41] [42] [43] but no mutations of these genes were found in our data. Previous germline mutation analysis using 160 PCa tumors from 77 families indicated that no pathogenic mutations in FH were identified. 44 Mutation or allelic loss of IDH1/2 was reported to be rare in localized PCa. 45 An immunohistochemical examination of SDHB loss in prostate tumors reported that only one case was found with SDHB-loss among the 57 prostate cancer cases, suggesting that SDHB-loss was extremely rare in PCa. 46 Thus, other regulatory mechanism must contribute to the altered metabolism in PCa that we observed.
Besides, a significant increased gene-metabolite association in PCTs but not in ANTs was observed. A joint analysis using metabolomic and transcriptomic data to study the gene-metabolites association revealed that many enzymemetabolite interactions were uniquely established in cancer and healthy states. 47 The enhanced metabolite-gene association in tumors may make them more adaptable to the harsh environment and make a quick response at the metabolic level when in metabolically distressed cancer cells. 47 In addition, we mapped the metabolites and genes to the TCA cycle and associated pathways and investigated the potential mechanism underlying activated TCA cycle. First, our finding showed an increased expression of ACO2 in tumor tissues. Previous studies have demonstrated that Tumor Markers and Signatures malignant cells no longer possess the ability to accumulate Zn 21 in the prostate, which relieves cis-aconitase from inhibition, the previously truncated TCA cycle is completed. 48 Another important route to control the flux into TCA cycle is from pyruvate. On the one hand, pyruvate can be transformed into acetyl CoA for citrate synthesis by the catalysis of PDH, 35 the expression of which was increased in PCTs. On the other hand, pyruvate can replenish TCA cycle by generating OAA through the catalysis of PC directly in the mitochondria. 49 It is noteworthy that the expression of BRP44 and BRP44L which encode the pyruvate transporters, was significantly elevated in PCTs, illustrating that enhanced pyruvate replenishment fuels the TCA cycle. Using multiple stable PC knockdown cell lines and 13C 6 -glucose and 13C 5 -glutamine labeled mass spectrometry analysis, it was revealed that PC played important roles in the pyruvate cycling and mitochondrial biosynthesis of precursors of cellular components required for cell growth and replication in invasive breast cancer. 50 Besides, the data indicated that the MYC-regulated Gln anaplerosis may contribute to fueling the TCA cycle by providing 2-KG in PCa. The observation that glutamine transporter ASCT1 (also called SLC1A4, FC 5 1.78, p 5 0.00016), GLS and glutamate dehydrogenase GLUD1, GLUD2 (Fig. 4a) were upregulated at the mRNA levels in PCa tissues was proof of the importance of this mechanism in PCa. 36 Another rote to replenish intermediate metabolite for TCA cycle was BCAA degradation. The expression of most genes (34/44) in BCAA degradation pathway was significantly increased in prostate tumor tissues. The gene that encodes mitochondrial BCAT2 (p 5 0.0072) was upregulated in tumor tissues, whereas the gene that encodes cytosolic BCAT1 (p 5 0.4781) was not significantly different relative to the normal tissue, suggesting preferential BCAA degradation in the mitochondria of PCa cells. Besides, correlation analysis indicated significant connections between the fumarate, malate and succinate levels and the expression of genes involved in the BCAA degradation pathway in tumor tissues, indicating that BCAA breakdown products may be incorporated into the TCA cycle. 38 Although additional in vitro or in vivo experiments were not performed to validate the functional consequence of our observed alterations, previous study revealed that altered BCAA metabolism drives cancer progression in myeloid leukaemia through the MSI2-BCAT1 axis. 51 BCAA can be utilized for energy production through a catabolic pathway regulated initially by BCAT, the activity of which was found altered in prostate cancer tissue relative to healthy tissue. 52 Thus, the study of BCAA metabolism and its association with TCA cycle may provide a new insight into prostate cancer carcinogenesis and novel therapeutic target for prostate cancer.
Accelerated TCA cycle is a unique characteristic in PCa cells. However, the molecular alterations of TCA cycle in metabolic and transcriptional levels and their correlations were rarely reported. Here, we revealed the dysregulation of metabolites and gene expression in PCa by integrating metabolomics and transcriptomics data. Not only the accumulations of metabolites including malate, fumarate, succinate and 2-HG and upregulation of gene expression were found in PCTs, but enhanced metabolite-gene associations were also observed. By mapping the metabolites and genes in TCA cycle and related pathways, we revealed several potential anaplerotic routes from pyruvate, glutamine catabolism and BCAA degradation contributing to replenishing metabolites for TCA cycle. To determine and verify the regulatory network underlying the accumulation of succinate, fumarate, malate and 2-HG, an indepth biological study remains needed and may provide new insight into PCa carcinogenesis.
